Quick Take
- Molbio Diagnostics opens its Rs 940 Cr ($98.7 Mn) IPO on August 10, price band Rs 768 to 807.
- Manipal Health listed at an 11% premium on August 5, closing near Rs 87,696 Cr market value.
- Ardee Industries crossed 14 times subscription by August 7; OfBusiness eyes a mid-November filing.
In This Article
The latest India IPO Updates for August 2026 show a busy primary market, with Molbio Diagnostics set to raise Rs 940 Cr ($98.7 Mn) from August 10 to 12, 2026, priced at Rs 768 to 807 per share. The Goa-based diagnostics firm files ahead of live debuts and fresh filings.
Momentum is clear across the week. Manipal Health Enterprises listed at an 11% premium on August 5, Ardee Industries sailed past 14 times subscription, and B2B unicorn OfBusiness is reviving its public-market plan. Each move signals rising investor appetite in a recovering IPO market, per company announcements and exchange data.
StartupFeed Insight
The real signal this week is not any single listing, it is the spread. Diagnostics, hospitals, metals recycling, and B2B commerce are all finding demand at once, which points to breadth returning rather than a narrow tech rally. Institutional books are doing the heavy lifting: Ardee’s QIB portion trailed while its NII portion ran past 30 times, and Manipal cleared on anchor strength despite thin retail. Watch Molbio’s subscription split from August 10, its Truenat platform gives it a rare export story. Expect at least three more new-age filings before Diwali 2026. By Harshvardhan Jain.
Today’s India IPO Updates At A Glance
These India IPO Updates cover one open issue, two recent debuts, and one fresh filing plan. All figures below are drawn from company announcements and BSE and NSE data as of August 7, 2026. USD conversions use the live rate of Rs 95.2 per US Dollar (BookMyForex, August 6, 2026).
| Company | Event | Key Figure | Status |
|---|---|---|---|
| Molbio Diagnostics | Mainboard IPO | Rs 940 Cr ($98.7 Mn) | Opens Aug 10, 2026 |
| Manipal Health | Listing debut | 11% premium, Rs 655 on BSE | Listed Aug 5, 2026 |
| Ardee Industries | Mainboard IPO | Rs 425.87 Cr, 14x-plus subscribed | Closes Aug 7, 2026 |
| OfBusiness | DRHP plan | $800 Mn (Rs 7,616 Cr) target | Filing eyed mid-Nov 2026 |
The most striking contrast is size versus speed. Manipal’s Rs 9,275 Cr issue dwarfed the others, yet Ardee’s far smaller book saw fiercer oversubscription in its non-institutional category.
About These Companies
Molbio Diagnostics, incorporated in 2000 and based in Verna, Goa, makes point-of-care molecular tests via its patented Truenat platform, covering tuberculosis, HIV, and over 30 diseases. It is backed by Temasek and Motilal Oswal Private Equity. Manipal Health, founded in 2010 and headquartered in Bengaluru, runs 49 hospitals with 13,037 beds. Ardee Industries, founded in 1993, recycles lead and non-ferrous scrap.
Why Is Molbio Diagnostics IPO Drawing Attention?
The Molbio Diagnostics IPO is a Rs 940 Cr book-built issue combining a Rs 200 Cr fresh issue and a Rs 740 Cr offer for sale (OFS). It opens on August 10 and closes on August 12, 2026, with anchor bidding on August 7 and a tentative listing on August 17, 2026, according to the company’s Red Herring Prospectus (RHP). At the upper band, it targets a valuation near Rs 9,300 Cr.
Molbio’s Truenat platform is patented in more than 100 countries and enables lab-grade PCR results within an hour in resource-limited settings, per its RHP filing.
The numbers explain the interest. Total income rose from Rs 840.66 Cr in FY24 to Rs 1,455.17 Cr in FY26, while profit after tax (PAT) climbed to Rs 164.14 Cr, the RHP shows. That combination of an export-ready product and rising profit is what sets Molbio apart from a typical diagnostics play. You can review the full Molbio Diagnostics Red Herring Prospectus before applying.
How Did Manipal Health And Ardee Perform?
Manipal Health Enterprises delivered the week’s marquee debut. Its shares listed at Rs 655 on the BSE on August 5, 2026, an 11.02% premium over the Rs 590 issue price, and closed near a Rs 87,696 Cr ($9.2 Bn) market value. The Rs 9,275.22 Cr issue was subscribed 4.92 times, powered by Rs 4,167 Cr in anchor demand, exchange data shows.
| Metric | Manipal Health | Ardee Industries |
|---|---|---|
| Issue size | Rs 9,275 Cr | Rs 425.87 Cr |
| Price band | Rs 560 to 590 | Rs 50 to 53 |
| Subscription | 4.92x (final) | 14x-plus (Day 3, open) |
| Listing | Listed Aug 5 (11% up) | Expected Aug 12 |
Ardee Industries, meanwhile, drew retail and non-institutional fervour. By the morning of August 7, its Rs 425.87 Cr issue had crossed 14 times overall, with the non-institutional portion running past 30 times even as the qualified institutional buyer (QIB) share stayed near 1.3 times, per BSE and NSE tallies. What sets Ardee apart is its circular-economy angle: it recovers critical metals from end-of-life batteries.
What’s Next
Molbio’s anchor book opens on August 7, with public bidding from August 10, so its subscription split will test appetite for profitable healthcare names. Ardee lists on August 12, 2026. OfBusiness is expected to file its DRHP by mid-November 2026. Which of these India IPO Updates will define the festive-season pipeline?
What Is Next In The IPO Pipeline?
The pipeline points firmly upward. B2B commerce unicorn OfBusiness is reviving its listing, targeting a DRHP filing by mid-November 2026 for a roughly $800 Mn (Rs 7,616 Cr) issue. Reports indicate the plan blends a fresh component of up to $260 Mn with an OFS by existing investors, at a targeted valuation in the $5 Bn to $6 Bn range.
For FY26, OfBusiness reported a 21% year-on-year rise in net profit to Rs 724 Cr, with revenue near Rs 20,645 Cr, based on its filed financials.
This status is a plan, not a confirmed filing, and the amount and structure may change before any DRHP reaches the Securities and Exchange Board of India (SEBI). Still, the revival mirrors a wider return of new-age firms to public markets. For the regulator’s live record of draft filings, see the SEBI public issues and DRHP filings page.
Investors can also confirm live listing and issue data directly on the BSE public issues portal, which carries official subscription and listing details.
Frequently Asked Questions
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StartupFeed and its authors are not SEBI-registered investment advisors. The analysis above is based on publicly available information and should not be the sole basis for any investment decision. Please consult a SEBI-registered financial advisor before making investment decisions.
Have a tip? Write to us at editorial@startupfeed.in.
